Immunitas Therapeutics, a US-based clinical stage precision immunotherapy company, announced on Thursday that it has named Annalisa D'Andrea, PhD as its new chief scientific officer (CSO).

Dr D'Andrea has over 25 years of basic and translational research and development expertise in both large and small pharmaceutical and biotech settings. She has around three decades of experience leading drug discovery and development. She also serves as a venture partner at Longwood Fund. She has held the position of president and CSO at ImmuneID, CSO at Kiniksa Pharmaceuticals and vice president and global head of Discovery for Immunology and Inflammation at Roche. She has served in multiple roles at SRI International and at Chiron Vaccines.

Amanda Wagner, Immunitas chief executive officer, said, 'Annalisa's leadership and deep drug development expertise has proven invaluable as we advanced our growing pipeline of novel precision immuno-oncology therapeutics over the past several months. We are excited to welcome her as our full-time chief scientific officer. Annalisa will spearhead translational development and progression of our research and discovery programs. Her experience will play a key role in shaping our scientific strategy as the company continues to bring novel differentiated therapies to patients.'